Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,235,338
  • Shares Outstanding, K 687,550
  • Annual Sales, $ 5,711 M
  • Annual Income, $ 700,160 K
  • 60-Month Beta 0.61
  • Price/Sales 2.23
  • Price/Cash Flow 11.14
  • Price/Book 1.55
Trade GRFS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.38
  • Number of Estimates 1
  • High Estimate 0.38
  • Low Estimate 0.38
  • Prior Year 0.31
  • Growth Rate Est. (year over year) +22.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.17 +10.25%
on 11/03/20
19.82 -4.49%
on 11/09/20
+1.71 (+9.93%)
since 11/02/20
3-Month
15.18 +24.70%
on 09/04/20
20.05 -5.59%
on 10/15/20
+2.93 (+18.31%)
since 09/02/20
52-Week
13.40 +41.27%
on 03/16/20
25.73 -26.43%
on 02/21/20
-3.72 (-16.42%)
since 12/02/19

Most Recent Stories

More News
Should Value Investors Consider Grifols (GRFS) Stock Now?

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

GRFS : 18.89 (-1.87%)
Report [2019-2026], Cell Surface Markers Market Size, Share, Growth, Trends, Revenue, Analysis, Competitive Landscape, Forecast

The rising investments for effective medicines is predicted to drive the global Cell Surface Markers Market during the forecast period, states Fortune Business Insights in a report. The growing cognizance...

ABCZY : 19.4000 (+2.75%)
GRFS : 18.89 (-1.87%)
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

, /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing...

GRF : 7.84 (+0.73%)
GRFS : 18.89 (-1.87%)
Grifols partners with TRC Healthcare to streamline intravenous compounding education

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for hospitals, clinics and compounding...

GRF : 7.84 (+0.73%)
GRFS : 18.89 (-1.87%)
Forget Bargain Hunting: Play 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

CI : 211.22 (+1.79%)
DRRX : 1.7900 (-2.19%)
GRFS : 18.89 (-1.87%)
PTI : 1.0500 (+2.94%)
CWBR : 1.2300 (unch)
GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS : 18.89 (-1.87%)
ZTS : 160.56 (-0.50%)
Thinking about buying stock in Staffing 360 Solutions, Electrameccanica Vehicles, Grifols SA, Newage Beverage, or Norwegian Cruise Line?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAF, SOLO, GRFS, NBEV, and NCLH.

GRFS : 18.89 (-1.87%)
NCLH : 23.05 (+0.48%)
STAF : 1.1000 (+0.92%)
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.84 (+0.73%)
GRFS : 18.89 (-1.87%)
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

- - - - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing...

GRF : 7.84 (+0.73%)
GRFS : 18.89 (-1.87%)
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

, and , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 7.84 (+0.73%)
GRFS : 18.89 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 19.77
1st Resistance Point 19.51
Last Price 18.89
1st Support Level 18.81
2nd Support Level 18.37

See More

52-Week High 25.73
Fibonacci 61.8% 21.02
Fibonacci 50% 19.56
Last Price 18.89
Fibonacci 38.2% 18.11
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar